<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">4H3g7mxrN8MqtZPMPQn3hWp</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2012000500018</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(12)09800518</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2012000500018</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Ponto de Vista</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Escores de risco nas interven&#231;&#245;es em valvopatia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Casalino</surname>
            <given-names>Ricardo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tarassoutchi</surname>
            <given-names>Fl&#225;vio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">SP</named-content>
        </addr-line>
        <institution content-type="orgname">InCo</institution>
        <country country="BR">Brasil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>05</month>
        <year>2012</year>
      </pub-date>
      <volume>98</volume>
      <issue>5</issue>
      <fpage>e84</fpage>
      <lpage>e86</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>11</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>03</month>
          <year>2012</year>
        </date>
        <date date-type="rev-recd">
          <day>12</day>
          <month>11</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Os escores de risco utilizados assistencialmente em cl&#237;nica de valvopatia j&#225; apresentam valida&#231;&#245;es em todo mundo, entretanto, os dados n&#227;o s&#227;o homog&#234;neos. As caracter&#237;sticas epidemiol&#243;gicas de cada popula&#231;&#227;o requerem uma valida&#231;&#227;o local dessas ferramentas de risco. A troca valvar percut&#226;nea, que j&#225; &#233; uma realidade em doen&#231;a valvar (principalmente na estenose a&#243;rtica), est&#225; indicada em pacientes com risco cir&#250;rgico elevado ou considerado proibitivo. Os estudos com essa nova estrat&#233;gia de tratamento utilizam os escores de risco como um dos crit&#233;rios de inclus&#227;o e s&#227;o escassos trabalhos que utilizam tais ferramentas como preditoras de risco. Os escores de risco depois de validados em suas respectivas popula&#231;&#245;es vieram para somar com a pr&#225;tica cl&#237;nica (individualiza&#231;&#227;o da conduta) na defini&#231;&#227;o da conduta em cl&#237;nica de valvopatia.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Medi&#231;&#227;o de risco</kwd>
        <kwd>doen&#231;as das valvas card&#237;acas</kwd>
        <kwd>doen&#231;as das valvas card&#237;acas</kwd>
        <kwd>estenose da valva a&#243;rtica</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>31</day>
        <month>07</month>
        <year>2012</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>PONTO DE VISTA</bold>
    </p>
    <p>Escores de risco nas interven&#231;&#245;es em valvopatia</p>
    <p>
      <bold>Ricardo Casalino; Fl&#225;vio Tarassoutchi</bold>
    </p>
    <p>InCor, S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Endere&#231;o para correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>Os escores de risco utilizados assistencialmente em cl&#237;nica de valvopatia j&#225; apresentam valida&#231;&#245;es em todo mundo, entretanto, os dados n&#227;o s&#227;o homog&#234;neos. As caracter&#237;sticas epidemiol&#243;gicas de cada popula&#231;&#227;o requerem uma valida&#231;&#227;o local dessas ferramentas de risco. A troca valvar percut&#226;nea, que j&#225; &#233; uma realidade em doen&#231;a valvar (principalmente na estenose a&#243;rtica), est&#225; indicada em pacientes com risco cir&#250;rgico elevado ou considerado proibitivo. Os estudos com essa nova estrat&#233;gia de tratamento utilizam os escores de risco como um dos crit&#233;rios de inclus&#227;o e s&#227;o escassos trabalhos que utilizam tais ferramentas como preditoras de risco. </p>
    <p> Os escores de risco depois de validados em suas respectivas popula&#231;&#245;es vieram para somar com a pr&#225;tica cl&#237;nica (individualiza&#231;&#227;o da conduta) na defini&#231;&#227;o da conduta em cl&#237;nica de valvopatia.</p>
    <p><bold>Palavras-chave:</bold> Medi&#231;&#227;o de risco, doen&#231;as das valvas card&#237;acas / cirurgia, doen&#231;as das valvas card&#237;acas / mortalidade, estenose da valva a&#243;rtica.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>Dados epidemiol&#243;gicos recentes evidenciam algumas mudan&#231;as no perfil dos portadores de doen&#231;as valvares que frequentam consult&#243;rios, enfermarias e unidades de pronto atendimento. Destacam-se a idade avan&#231;ada e a quantidade de comorbidades que elevam o risco cir&#250;rgico do paciente.</p>
    <p>Deste modo, a estratifica&#231;&#227;o de risco pr&#233;-operat&#243;ria &#233; fundamental e auxilia na tomada de decis&#227;o direcionada para o paciente, levando em conta seus fatores de risco, chances de complica&#231;&#245;es e mortalidade.</p>
    <p>Al&#233;m do uso assistencial dos escores de risco para predi&#231;&#227;o de morbimortalidade nos valvopatas, estes modelos s&#227;o utilizados como crit&#233;rio de inclus&#227;o para os recentes estudos com as novas estrat&#233;gias de substitui&#231;&#227;o valvar<sup>1,2</sup>. Diante desse fato, surge uma d&#250;vida: os escores de risco est&#227;o avaliando de maneira adequada os valvopatas em diferentes institui&#231;&#245;es?</p>
    <p>
      <bold>Escores de risco</bold>
    </p>
    <p>Os escores mais utilizados no contexto da cirurgia valvar s&#227;o: o <italic>Euroscore</italic><sup><italic>3</italic></sup>, <italic>STS score</italic><sup>4,5</sup><italic>e Ambler score</italic><sup>6</sup>. Cada escore apresenta suas especifica&#231;&#245;es. O <italic>Euroscore</italic> surgiu do banco de dados europeu com aproximadamente 19.000 pacientes, destes 29% foram submetidos &#224; cirurgia valvar e sua valida&#231;&#227;o inicial foi feita com 1.497 pacientes de forma prospectiva. <italic>O</italic> Euroscore aditivo &#233; um c&#225;lculo matem&#225;tico simples e a forma log&#237;stica necessita de um computador (algoritmo complexo com as mesmas vari&#225;veis). O <italic>STS score</italic> foi gerado a partir do banco de dados americano, separado em tr&#234;s grandes coortes com mais 100.000 pacientes cada. Nos grupos 2 e 3, foram inclu&#237;dos respectivamente apenas cirurgias valvares (troca valvar a&#243;rtica, troca valvar mitral e reparo mitral) e a combina&#231;&#227;o de cirurgia valvar e revasculariza&#231;&#227;o. O <italic>Ambler Score</italic> teve como base o banco de dados cir&#250;rgico do Reino Unido com mais de 32.000 pacientes, todos portadores de doen&#231;as valvares.</p>
    <p>Com objetivo de predizer mortalidade p&#243;s-operat&#243;ria (desfecho principal), as vari&#225;veis do paciente e do procedimento cir&#250;rgico que comp&#245;em os modelos de risco,foram escolhidas ap&#243;s an&#225;lises uni e multivariada (<xref ref-type="table" rid="t01">Tabela 1</xref>). O desempenho dos escores &#233; avaliado pela &#225;rea sob a curva ROC (ASCR) e visa diferenciar os pacientes de baixo e alto risco de complica&#231;&#245;es (maior risco de ocorr&#234;ncia do desfecho). A ASRC igual &#224; unidade significa 100% de acerto na capacidade preditiva. A capacidade discriminativa predita pelos escores nas valida&#231;&#245;es iniciais foi considerada de boa a muito boa - ASCR de 0,72, 0,72, 0,77 e 0,80, respectivamente para <italic>Euroscore aditivo, log&#237;stico, Ambler e STS.</italic></p>
    <p content-type="asset">
      <table-wrap id="t01">
        <graphic xlink:href="1678-4170-abc-98-05-0e84-00018-gt01.jpg"/></table-wrap>
    </p>
    <p>Outra metodologia utilizada na valida&#231;&#227;o de escores de risco &#233; a calibra&#231;&#227;o, na qual se comparam as mortalidades preditas pelo escore e a observada na popula&#231;&#227;o estudada. O m&#233;todo mais comumente utilizado &#233; o <italic>Hosmer-lemeshow</italic>. Espera-se que as mortalidades observadas e preditas sejam iguais do ponto de vista estat&#237;stico (p &gt; 0,05). Nas respectivas valida&#231;&#245;es, os escores apresentaram boa calibra&#231;&#227;o. Entretanto, em outras an&#225;lises com diferentes popula&#231;&#245;es, o <italic>Euroscore log&#237;stico e o Ambler</italic> superestimaram a mortalidade, enquanto que o STS a subestimou.</p>
    <p>Vale ressaltar que existem diferen&#231;as entre nossos pacientes e a popula&#231;&#227;o avaliada nos estudos iniciais de valida&#231;&#227;o dos escores de risco. Destacam-se a idade mais jovem de nossos pacientes, o predom&#237;nio da etiologia reum&#225;tica, que aumenta a frequ&#234;ncia de procedimentos combinados (mitro-a&#243;rtica e mitro-tric&#250;spideo) e a quantidade de reopera&#231;&#245;es<sup>7</sup>. Essas considera&#231;&#245;es s&#227;o importantes pela possibilidade de mudar as porcentagens dos pacientes de baixo e alto risco e podem prejudicar a acur&#225;cia do escore em nossa popula&#231;&#227;o. Entretanto, quando o <italic>Euroscore</italic> foi aplicado em popula&#231;&#227;o brasileira apresentou ASRC de 0,73, ou seja, capacidade discriminativa boa<sup>8</sup>.</p>
    <p>Apesar de objetivo, existem limita&#231;&#245;es na aplicabilidade do escore &#224; beira do leito e a individualiza&#231;&#227;o da conduta &#233; fundamental. Cada vari&#225;vel tem um peso que &#233; compar&#225;vel quando utilizamos o escore, mas, do ponto de vista da pr&#225;tica cl&#237;nica, esta compara&#231;&#227;o pode ser imprecisa. Um exemplo dessa imprecis&#227;o foi o de paciente com 60 anos e disfun&#231;&#227;o ventricular esquerda grave, que teve <italic>Euroscore aditivo de</italic> 4 e o de paciente com 73 anos, feminina, sem comorbidades, que teve no <italic>Euroscore aditivo os mesmos</italic> 4 pontos. Definitivamente, n&#227;o s&#227;o pacientes com o mesmo risco operat&#243;rio, apesar de apresentarem a mesma pontua&#231;&#227;o pelo <italic>Euroscore.</italic></p>
    <p>
      <bold>Novos procedimentos</bold>
    </p>
    <p>O procedimento percut&#226;neo veio preencher uma lacuna complicada para os cl&#237;nicos e cirurgi&#245;es na indica&#231;&#227;o cir&#250;rgica na doen&#231;a valvar. At&#233; 35% dos portadores de estenose a&#243;rtica grave, idosos e com comorbidades significativas n&#227;o s&#227;o submetidos a quaisquer procedimentos pelo alto risco operat&#243;rio<sup>9</sup>.</p>
    <p>Com esse prop&#243;sito, a terapia percut&#226;nea (troca valvar percut&#226;nea) foi testada e comprovada como procedimento eleg&#237;vel na estenose a&#243;rtica de risco operat&#243;rio elevado. A evid&#234;ncia foi gerada por relatos de casos, registros e um trabalho prospectivo<sup>1,2</sup>. A avalia&#231;&#227;o de risco de cada paciente era determinada pela equipe cir&#250;rgica respons&#225;vel em cada centro e esperava-se um risco m&#237;nimo de 15% de mortalidade perioperat&#243;ria (at&#233; 30 dias p&#243;s-procedimento). Para deixar a amostra mais homog&#234;nea com rela&#231;&#227;o &#224; predi&#231;&#227;o de risco, utilizou-se o <italic>STS</italic> de no m&#237;nimo 10% como crit&#233;rio de inclus&#227;o. Os pacientes foram randomizados para receber quaisquer das terapias (cirurgia ou troca percut&#226;nea)<sup>1,2</sup>. Foi um estudo de n&#227;o inferioridade em que n&#227;o ocorreu diferen&#231;a entre os procedimentos testados em at&#233; um ano de seguimento. Apesar do uso dos escores nesse trabalho, devemos saber que as publica&#231;&#245;es que validaram o uso cl&#237;nico destas ferramentas n&#227;o inclu&#237;ram nenhum caso de troca percut&#226;nea. Logo, o uso dos escores para predizer morte nesses pacientes &#233; considerado uma extrapola&#231;&#227;o de dados.</p>
    <p>Um estudo retrospectivo holand&#234;s com 168 casos submetidos &#224; troca valvar percut&#226;nea tentou avaliar o desempenho do <italic>Euroscore</italic> log&#237;stico e do <italic>STS</italic> na capacidade de predizer mortalidade e obteve resultados pouco impactantes com ASCR de 0,49 e 0,69 respectivamente<sup>10</sup>.</p>
    <p>
      <bold>Considera&#231;&#245;es finais e perspectivas</bold>
    </p>
    <p>A estratifica&#231;&#227;o pr&#233;-operat&#243;ria na cirurgia &#233; elemento fundamental, pois &#233; uma forma de prever eventos e, se poss&#237;vel, programar interven&#231;&#245;es. Para tal, as ferramentas devem ser validadas em suas respectivas institui&#231;&#245;es (locais com baixo e alto volume de pacientes; propor&#231;&#245;es adequadas dos percentis de risco) e de prefer&#234;ncia serem atualizadas continuamente.</p>
    <p>O tratamento percut&#226;neo &#233; procedimento completamente diferente da cirurgia e tais escores de risco n&#227;o devem ser as &#250;nicas ferramentas utilizadas na tomada de decis&#227;o em cl&#237;nica de valvopatia. Com aumento do volume desse procedimento, os dados gerados podem levar a confec&#231;&#245;es de novas ferramentas preditoras de risco.</p>
    <p>Portanto, apesar das limita&#231;&#245;es, os escores de risco quando devidamente utilizados e interpretados s&#227;o ferramentas &#250;teis na pr&#225;tica cl&#237;nica.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Doutorado de Ricardo Casalino e Fl&#225;vio Tarassoutchi pelo Instituto do Cora&#231;&#227;o - InCor - FMUSP.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Endere&#231;o para correspond&#234;ncia:</p>
        <p> Ricardo Casalino </p>
        <p> Rua Capote Valente, 442 - Pinheiros </p>
        <p> 05409-001 - S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="ricardocasalino@cardiol.br">ricardocasalino@cardiol.br</email>, </p>
        <p>
          <email xlink:href="ricardocasalino@gmail.com">ricardocasalino@gmail.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 10/11/11 </p>
    <p> Revisado recebido em 12/11/12 </p>
    <p> Aceito em 15/03/12</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Leon MB, Smith    CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aorticvalve    implantation for aortic stenosis in patients who cannot undergo surgery. N Engl    J Med. 2010;363(17):1597-607.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Transcatheter aorticvalve implantation for aortic stenosis in patients who cannot undergo surgery</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>1597</fpage>
          <lpage>607</lpage>
          <issue>17</issue>
          <volume>363</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Leon</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Mack</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Moses</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Svensson</surname>
              <given-names>LG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Smith CR, Leon    MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical    aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187-98.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Transcatheter versus surgical aortic-valve replacement in high-risk patients</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2011</year>
          </date>
          <fpage>2187</fpage>
          <lpage>98</lpage>
          <issue>23</issue>
          <volume>364</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Leon</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Mack</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Moses</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Svensson</surname>
              <given-names>LG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Nashef SA, Roques    F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac    operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16(1):9-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>European system for cardiac operative risk evaluation (EuroSCORE)</article-title>
          <source>Eur J Cardiothorac Surg</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>9</fpage>
          <lpage>13</lpage>
          <issue>1</issue>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nashef</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Roques</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Michel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gauducheau</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lemeshow</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Salamon</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. O'Brien SM,    Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. The Society of    Thoracic Surgeons 2008 cardiac surgery risk models: part 2&#8212;isolated    valve surgery. Ann Thorac Surg. 2009;88(1 Suppl):S23-42.</mixed-citation>
        <element-citation publication-type="journal">
          <source>Ann Thorac Surg</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>S23</fpage>
          <lpage>42</lpage>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>O'Brien</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Shahian</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Filardo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ferraris</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Haan</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Rich</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Shahian DM,    O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. The Society of    Thoracic Surgeons 2008 cardiac surgery risk models: part 3&#8212;valve    plus coronary artery bypass grafting surgery. Ann Thorac Surg. 2009;88(1 Suppl):S23-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 3-valve plus coronary artery bypass grafting surgery</article-title>
          <source>Ann Thorac Surg</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>S23</fpage>
          <lpage>42</lpage>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shahian</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>O'Brien</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Filardo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ferraris</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Haan</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Rich</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Ambler G, Omar    RZ, Royston P, Kinsman R, Keogh BE, Taylor KM. Generic, simple risk stratification    model for heart valve surgery. Circulation. 2005;112(2):224-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Generic, simple risk stratification model for heart valve surgery</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>224</fpage>
          <lpage>31</lpage>
          <issue>2</issue>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ambler</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Omar</surname>
              <given-names>RZ</given-names>
            </name>
            <name>
              <surname>Royston</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kinsman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Keogh</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Tarasoutchi    F, Montera MW, Grinberg M, Barbosa MR, Pi&#241;eiro DJ, S&#225;nchez CRM,    et al.; Sociedade Brasileira de Cardiologia. Diretriz brasileira de valvopatias    - SBC 2011. / I Diretriz Interamericana de Valvopatias - SIAC 2011. Arq Bras    Cardiol. 2011;97(5 supl. 3):1-67.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>; Sociedade Brasileira de Cardiologia: Diretriz brasileira de valvopatias - SBC 2011. / I Diretriz Interamericana de Valvopatias - SIAC 2011</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2011</year>
          </date>
          <fpage>1</fpage>
          <lpage>67</lpage>
          <issue>5</issue>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tarasoutchi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Montera</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Grinberg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Barbosa</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Pi&#241;eiro</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>S&#225;nchez</surname>
              <given-names>CRM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Andrade ING,    Moraes Neto FR, Oliveira JPSP, Silva ITC, Andrade TG, Moraes CRR. Avalia&#231;&#227;o    do EuroSCORE como preditor de mortalidade em cirurgia card&#237;aca valvar    no Instituto do Cora&#231;&#227;o de Pernambuco. Rev Bras Cir Cardiovasc.    2010;25(1):11-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Avalia&#231;&#227;o do EuroSCORE como preditor de mortalidade em cirurgia card&#237;aca valvar no Instituto do Cora&#231;&#227;o de Pernambuco</article-title>
          <source>Rev Bras Cir Cardiovasc</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>11</fpage>
          <lpage>8</lpage>
          <issue>1</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Andrade</surname>
              <given-names>ING</given-names>
            </name>
            <name>
              <surname>Moraes Neto</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>JPSP</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>ITC</given-names>
            </name>
            <name>
              <surname>Andrade</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Moraes</surname>
              <given-names>CRR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Rosenhek R,    Iung B, Tornos P, Antunes MJ, Prendergast BD, Otto CM, et al. ESC Working Group    on Valvular Heart Disease Position Paper: assessing the risk of interventions    in patients with valvular heart disease. Eur Heart J. 2011; 33(7):822-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2011</year>
          </date>
          <fpage>822</fpage>
          <lpage>8</lpage>
          <issue>7</issue>
          <volume>33</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rosenhek</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Iung</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tornos</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Antunes</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Prendergast</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Otto</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Piazza N, Wenaweser    P, van Gameren M, Pilgrim T, Tzikas A, Otten A, et al. Relationship between    the logistic EuroSCORE and the Society of Thoracic Surgeons predicted risk of    mortality score in patients implanted with CoreValve ReValving system&#8212;A    Bern Rotterdam Study. Am Heart J. 2010;159(2):323-9.</mixed-citation>
        <element-citation publication-type="journal">
          <source>Am Heart J</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>323</fpage>
          <lpage>9.</lpage>
          <issue>2</issue>
          <volume>159</volume>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Point of View</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Risk scores in valvular heart disease interventions</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>The risk scores used as assistance agents in valve diseases are validated worldwide; however, the data are not homogeneous. The epidemiological characteristics of each population require local validation of these risk tools. The percutaneous valve replacement, which is a reality in valvular diseases (especially aortic stenosis), is indicated for patients with high or prohibitive surgical risk. Studies with this new treatment strategy use risk scores as criteria for inclusion and there are few studies that use such tools as predictors of risk. The risk scores, after due validation in their relevant populations, are combined with clinical practice (individualization of conduct) in the definition of the conduct to be adopted in the clinical practice of valvular heart disease.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Risk assessment</kwd>
        <kwd>heart valve diseases</kwd>
        <kwd>heart valve diseases</kwd>
        <kwd>aortic valve stenosis</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>POINT OF VIEW</bold>
      </p>
      <p><undefined id="top-body2"/>Risk scores in valvular heart disease interventions</p>
      <p>
        <bold>Ricardo Casalino; Fl&#225;vio Tarassoutchi</bold>
      </p>
      <p>InCor, S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondence</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>The risk scores used as assistance agents in valve diseases are validated worldwide; however, the data are not homogeneous. The epidemiological characteristics of each population require local validation of these risk tools. The percutaneous valve replacement, which is a reality in valvular diseases (especially aortic stenosis), is indicated for patients with high or prohibitive surgical risk. Studies with this new treatment strategy use risk scores as criteria for inclusion and there are few studies that use such tools as predictors of risk.</p>
      <p> The risk scores, after due validation in their relevant populations, are combined with clinical practice (individualization of conduct) in the definition of the conduct to be adopted in the clinical practice of valvular heart disease.</p>
      <p><bold>Keywords:</bold> Risk assessment; heart valve diseases / surgery; heart valve diseases / mortality; aortic valve stenosis.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Recent epidemiological data show some changes in the profile of patients with valvular disease who attend clinics, wards and emergency units. Worthy of note is the age and number of comorbidities that increase patient's surgical risk.</p>
      <p>Thus, preoperative risk stratification is critical and assists in decision-making directed towards the patient, taking into account their risk factors, chances of complications and mortality.</p>
      <p>Besides the use of risk scores to predict morbidity and mortality in heart valve disease patients, these models are used as criteria for inclusion in the recent studies with new strategies of valve replacement<sup>1,2</sup>. Given this fact, a question arises: are risk scores assessing properly the heart valve disease in different institutions? </p>
      <p>
        <bold>Risk scores</bold>
      </p>
      <p>The scores mostly used in the context of valve surgery are: Euroscore<sup>3</sup>, STS score<sup>4,5</sup> and Ambler score<sup>6</sup>. Each score has its specifications. The Euroscore emerged from the European database with approximately 19,000 patients. Out of these, 29% underwent valve surgery and it was first validated with 1,497 patients prospectively. The additive Euroscore is a simple mathematical calculation and the logistics form requires a computer (complex algorithm with the same variables).The STS score was generated from the U.S. database separated into three large cohorts with more than 100,000 patients each. In groups 2 and 3, only valve surgeries (aortic valve replacement, mitral valve replacement and mitral valve repair), and combined valve surgery and coronary artery bypass grafting were respectively included. The Ambler score was based on the surgical database of the United Kingdom with more than 32,000 patients, all suffering from valve disease.</p>
      <p>In order to predict postoperative mortality (primary outcome), the variables of patient and surgical procedure that comprise the risk models were chosen after univariate and multivariate analyzes (<xref ref-type="table" rid="eng18t01-body2">Table 1</xref>). The performance of scores is evaluated by the area under the ROC curve (AUC) and aims to differentiate patients with low or high risk of complications (increased risk of occurrence of the outcome). The AUC equal to the unit means 100% of accurate predictive ability. The discriminative capacity predicted by the scores on the initial validations was considered good to very good - AUC of 0.72, 0.72, 0.77 and 0.80, respectively, for additive and logistic Euroscore, Ambler and STS.</p>
      <p content-type="asset">
        <table-wrap id="eng18t01-body2">
          <graphic xlink:href="1678-4170-abc-98-05-0e84-00018-gt01-en.jpg"/></table-wrap>
      </p>
      <p>Another methodology used in the validation of risk scores is the calibration, in which we compare the mortality predicted by the score and that observed in the population studied. The most commonly used method is the Hosmer-Lemeshow test. It is expected that the observed and predicted mortality be equal from a statistical viewpoint (p &gt; 0.05). In their validations, the scores showed good calibration. However, in other analyzes with different populations, the Ambler and logistic Euroscore overestimated mortality, while the STS underestimated it.</p>
      <p>It is noteworthy that there are differences between our patients and the population evaluated in the initial studies that validate the risk scores. Worthy of note is the younger age of our patients, the prevalence of rheumatic etiology, which increases the frequency of combined procedures (mitral and aortic and mitral and tricuspid) and the amount of reoperations<sup>7</sup>. These considerations are important because of the possibility of changing the percentages of patients at low and high risk and may affect the accuracy of the score in our population. However, when the Euroscore was applied in the Brazilian population, it showed ASRC of 0.73, i.e., good discriminative capacity<sup>8</sup>.</p>
      <p>Although it is objective, there are limitations on the applicability of the score at the bedside and individualized approach is fundamental. Each variable has a weight that is comparable when using the score, but from the standpoint of clinical practice, this comparison may be inaccurate. An example of this inaccuracy was that of a patient aged 60 years and severe left ventricular dysfunction, which had an additive Euroscore of 4 and that of a female patient aged 73 with no comorbidities, who had an additive Euroscore of four points, as well. Definitely, these patients do not have the same operative risk, although they have the same Euroscore.</p>
      <p>
        <bold>New procedures</bold>
      </p>
      <p>The percutaneous procedure fills a gap complicated for surgeons and physicians in the surgical indication in valvular heart disease. Up to 35% of patients with severe aortic stenosis, elderly patients and those with significant comorbidities are not subjected to any procedures at high operative risk<sup>9</sup>.</p>
      <p>For this purpose, percutaneous therapy (percutaneous valve replacement) was tested and confirmed as an eligible procedure in aortic stenosis of high operative risk. The evidence was generated by case reports, records and a prospective work<sup>1,2</sup>. The risk assessment of each patient was determined by the surgical team responsible for each center and a minimum of 15% risk of preoperative mortality was expected (30 days post-procedure). To make the sample more homogeneous with respect to risk prediction, we used the STS of at least 10% as inclusion criteria. Patients were randomized to receive any of the therapies (surgery or percutaneous exchange)<sup>1,2</sup>. It was a non-inferiority study in which there was no difference among the procedures tested within one year of follow-up. Despite the use of scores in this work, we should know that the publications that have validated the clinical use of these tools did not include any cases of percutaneous procedure. Thus, the use of the scores to predict death in these patients is considered data extrapolation.</p>
      <p>A Dutch retrospective study with 168 patients who underwent percutaneous valve replacement attempted to evaluate the performance of the logistic Euroscore and STS in predicting mortality and obtained some striking results with AUC of 0.49 and 0.69, respectively<sup>10</sup>.</p>
      <p>
        <bold>Concluding remarks and perspectives</bold>
      </p>
      <p>Preoperative stratification in surgery is fundamental because it is a way to predict events and, if possible, plan interventions. To this end, the tools must be validated in their respective institutions (sites with low and high volume of patients; proportions proper to the percentile of risk) and should preferably be updated continuously.</p>
      <p>The percutaneous procedure is completely different from the surgery and such risk scores should not be the only tools used in clinical decision-making in valve disease. With increase in the volume of that procedure, the data generated may lead to new risk prediction tools.</p>
      <p>Therefore, despite these limitations, when risk scores are properly used and interpreted are useful tools in clinical practice.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of Doctoral submitted by Ricardo Casalino and Fl&#225;vio Tarassoutchi, from Instituto do Cora&#231;&#227;o - InCor - FMUSP.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
